Skip to main navigation
Home

Search form

  • About Us

    • Profile & Mission

    • Our Strategy

    • Leadership Team

    • Company Histroy

  • Our Products

  • Cumberland Emerging Technologies

  • Investor Relations

    Investor Relations

    • Investor Relations
    • Corporate Update
    • Corporate Governance
      • Committees
      • Contact the Board
    • Stock Information
      • Historic Stock Lookup
      • Ownership Profile
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
      • Key Ratios
    • Events & Presentations
    • Investor FAQs
    • Press Releases
    • Contact IR
    3 Mo. 6 Mo. 1 Yr.

    Shareholder Tools

    Search Investor Relations

  • News

  • Blog

  • Contact Us

    Corporate Headquarters

    Cumberland Pharmaceuticals Inc.
    2525 West End Avenue, Suite 950
    Nashville, Tennessee 37203

    Phone: (615) 255-0068
    Toll Free: (877) 484-2700
    Fax: (615) 255-0094

    info@cumberlandpharma.com

    *For directions to us, please see Location

    Employment Opportunities

    employment@cumberlandpharma.com

    Investor Relations

    investors@cumberlandpharma.com

    Business Development

    development@cumberlandpharma.com

    Wholesaler Customer Service

    Phone: (877) 274-7200
    Fax: (614) 652-9127

    Medical Information

    This website is not for medical emergencies. If you are a patient, caregiver or healthcare professional and need product related information, please visit our Products page, which will link you to product-specific websites.

    Adverse Event Reporting

    Toll Free Phone: (866) 767-5077
    (For healthcare professionals only)

     

     

Investor Relations

  • Investor Relations
  • Corporate Update
  • Corporate Governance
    • Committees
    • Contact the Board
  • Stock Information
    • Historic Stock Lookup
    • Ownership Profile
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
    • Key Ratios
  • Events & Presentations
  • Investor FAQs
  • Press Releases
  • Contact IR
3 Mo. 6 Mo. 1 Yr.

Shareholder Tools

Search Investor Relations

 

News

In the News

IV Form of NAC Receives FDA sNDA to Prevent, Lessen Liver Injury After Ingesting Toxic Quantities of Acetaminophen 135.2 KB
Dec 10, 2024
New Dosing Regimen for APAP Overdose Antidote Acetadote Approved 158.4 KB
Dec 10, 2024
Ibuprofen injection shows better real-world outcomes in comparative study 4.6 MB
Nov 19, 2024
FDA Grants Orphan Drug Designation to lfetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy 171.6 KB
Nov 08, 2024
Cumberland Pharmaceuticals granted Orphan Drug Designation and Rare Pediatric Disease Designation for lfetroban 257.3 KB
Nov 07, 2024
CPIX: A Solid Stock With An Exciting Catalyst 182.8 KB
May 31, 2023
Recent 2023 FDA Approvals 410.8 KB
May 30, 2023
Caldolor gains FDA nod for infant treatment 134 KB
May 30, 2023
Cumberland to launch Phase II trial of ifetroban for IPF 258.7 KB
May 30, 2023
Nashville Post - In Charge 641.6 KB
May 23, 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 20
Cumberland Pharmaceuticals Inc. 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203
Site MapPrivacy PolicyTerms & Conditions